2022 World Conference on Lung Cancer (ePosters)-EP08.01-031. Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

EP08.01-031. Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

Back to course

Pdf Summary

A study was conducted to investigate changes in gene expression in the blood of patients with metastatic non-small cell lung cancer (NSCLC) who underwent second-line immunotherapy. The study included 25 patients who received either pembrolizumab or nivolumab as a second-line treatment. Blood samples were collected at baseline and after four cycles of immunotherapy, and gene expression analysis was performed.<br /><br />The results showed that compared to newly diagnosed cases, patients with metastatic NSCLC starting second-line immunotherapy had increased expression of various genes involved in immune responses. These genes included FAS, RORgt, IFNγ, FASLv1, PRF1, PD1, CD247, GZMB, TBX21, and GATA3, suggesting systemic immune activation in these patients.<br /><br />Additionally, the study found that second-line treatment led to a significant increase in the expression of the MKI67 gene and a decrease in the expression of the RORgt gene. These changes in gene expression were found to correlate better with long-lasting responses to immunotherapy compared to changes in blood cell counts.<br /><br />The study's findings are currently being validated in a larger prospective study. The researchers noted that the expression of immune-related genes in the blood could serve as potential biomarkers to predict the clinical benefit of immunotherapy in patients with metastatic NSCLC.<br /><br />The study provides valuable insights into the changes in gene expression in the blood of patients undergoing second-line immunotherapy for metastatic NSCLC. Further research is needed to validate these findings and determine the clinical implications for patient management.

Asset Subtitle

Fabienne Dorothea Lusky

Meta Tag

Speaker Fabienne Dorothea Lusky

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

gene expression

metastatic non-small cell lung cancer

second-line immunotherapy

immune responses

FAS

RORgt

MKI67 gene

RORgt gene

biomarkers

clinical benefit